TELA Bio, Inc. (TELA) Earnings Call Analysis
NASDAQ · Healthcare · Medical Devices
Earnings Reports
-
Telebio (TELA) Q1 2026: 41% International Surge Validates Commercial Reset and Portfolio Expansion
May 13, 2026
-
Telebio (TELA) Q4 2025: 40% New Rep Cohort Drives Commercial Reset, 8% Growth Guide Signals Cautious Ramp
March 25, 2026
-
Telebio (TELA) Q3 2025: Salesforce Expands to 76 Territory Managers, Driving Foundation for 15%+ Growth
November 14, 2025
-
TELA Bio (TELA) Q2 2025: PRS Revenue Jumps 53% as Patient-Centric Model Reshapes Growth Trajectory
August 11, 2025